Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 19 of the 49 sources its claims cite were checked for support.

The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes

Open access
Santos, Marlene, Lima, Luis, Carvalho, Serafim, Mota-Pereira, Jorge, Pimentel, Paulo, Maia, Dulce, Correia, Diana, Barroso, M. Fátima, Gomes, Sofia, Cruz, Agostinho, Medeiros, Rui · 2023 · International Journal of Molecular Sciences

Abstract

This study aimed to investigate the influence of genetic variants in neuroplasticity-related genes on antidepressant treatment phenotypes. The BDNF-TrkB signaling pathway, as well as the downstream kinases Akt and ERK and the mTOR pathway, have been implicated in depression and neuroplasticity. However, clinicians still struggle with the unpredictability of antidepressant responses in depressed patients. We genotyped 26 polymorphisms in BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 in 80 patients with major depressive disorder treated according to the Texas Medical Algorithm for 27 months at Hospital Magalhães Lemos, Porto, Portugal. Our results showed that BDNF rs6265, PTEN rs12569998, and SYN1 rs1142636 SNP were associated with treatment-resistant depression (TRD). Additionally, MAPK1 rs6928 and GSK3B rs6438552 gene polymorphisms were associated with relapse. Moreover, we found a link between the rs6928 MAPK1 polymorphism and time to relapse. These findings suggest that the BDNF, PTEN, and SYN1 genes may play a role in the development of TRD, while MAPK1 and GSK3B may be associated with relapse. GO analysis revealed enrichment in synaptic and trans-synaptic transmission pathways and glutamate receptor activity with TRD-associated genes. Genetic variants in these genes could potentially be incorporated into predictive models of antidepressant response.

Overview

CoChat Summary

TL;DR

In 80 Portuguese patients with major depressive disorder followed for 27 months on the Texas Medication Algorithm, polymorphisms in BDNF, PTEN, and SYN1 were associated with treatment-resistant depression, while MAPK1 and GSK3B were associated with relapse. Functional enrichment implicated synaptic and trans-synaptic transmission and glutamate receptor activity.

Key findings

  • BDNF rs6265 CT genotype was associated with TRD (OR: 3.2; 95% CI: 0.975–10.501; p = 0.049); PTEN rs12569998 TG genotype was associated with TRD (OR: 4.231; 95% CI: 1.173–15.261; p = 0.020); SYN1 rs1142636 GG genotype was associated with TRD (OR: 6.00; 95% CI: 1.543–23.333; p = 0.006), as was the G allele (OR: 3.120; 95% CI: 1.045–9.314; p = 0.037).
  • MAPK1 rs6928 C allele carriers had reduced relapse risk (OR: 0.303; 95% CI: 0.090–1.020; p = 0.048) and relapsed later than GG carriers (100 vs. 82 weeks, p = 0.022, log-rank).
  • GSK3B rs6438552 GG genotype was associated with relapse (OR: 6.667; 95% CI: 1.121–39.660; p = 0.042), as was the G allele (OR: 5.600; 95% CI: 1.137–27.571; p = 0.033).
  • GO analysis of TRD-associated genes showed enrichment in chemical synaptic transmission, anterograde trans-synaptic signaling, glutamate receptor signaling, neuron projections, dendrites, and ionotropic glutamate receptor complexes.

Methods

  • Candidate-gene pharmacogenetic cohort study of 80 MDD patients recruited at Hospital Magalhães Lemos, Oporto, Portugal, followed for 27 months and treated according to the Texas Medication Algorithm; diagnosis used SCID-I and severity used BDI. Evaluated phenotypes included remission, TRD, time to remission, relapse, and time to relapse.
  • Genotyped 26 polymorphisms in BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 using the Sequenom MassARRAY platform; 10% of samples were repeated for quality control with the same results.
  • Statistical analysis used chi-square tests, odds ratios with 95% confidence intervals, Kaplan–Meier survival curves with log-rank tests, and Hardy–Weinberg equilibrium testing; Geneshot and Enrichr were used for GO and KEGG enrichment analyses.

Limitations

  • The paper states the sample is small, so small effects of single SNPs may not be detected; only a few SNPs per gene were evaluated due to the target-pathway design; and because drugs with different mechanisms of action were used, each SNP could not be correlated with a specific antidepressant class.
  • Evident from the text: no correction for multiple comparisons is reported despite testing 26 polymorphisms across multiple treatment phenotypes, and the findings are candidate-gene associations in a small cohort that require replication.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms24076758

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Effect of MAPK1 rs6928 genotypes in time to relapse in MDD patients. Kaplan–Meier analysis was used to evaluate the association between time to relapse and MAPK1 rs6928 GG and GC + CC carriers. Comparison performed by Log-rank test (p = 0.022).
Figure 1 Effect of MAPK1 rs6928 genotypes in time to relapse in MDD patients. Kaplan–Meier analysis was used to evaluate the association between time to relapse and MAPK1 rs6928 GG and GC + CC carriers. Comparison performed by Log-rank test (p = 0.022).CC BY · PubMed Central
Figure 2 Bar chart of top enriched terms from the KEGG_2021_Human gene set library. The top 10 enriched terms for the input gene set are displayed based on the -log10 (p-value), with the actual p-value shown next to each term (*). The term at the top has the most significant overlap with the input query gene set.
Figure 2 Bar chart of top enriched terms from the KEGG_2021_Human gene set library. The top 10 enriched terms for the input gene set are displayed based on the -log10 (p-value), with the actual p-value shown next to each term (*). The term at the top has the most significant overlap with the input query gene set.CC BY · PubMed Central

Verification

Claims the paper makes

17 Valid · 1 Not valid · 14 Not checked · 36 Own results and interpretations

35 more claims

Create a free account to see all 68 claims and to verify the 7 references still open.

See all claims — free account
  • Probably not a substantial claim. 21
  • It may state two separate claims as one. 16

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 70 references

Research works printed but not linked: 1

  1. Gabriel, S., Ziaugra, L., and Tabbaa, D. (2001). Current Protocols in Human Genetics, John Wiley & Sons, Inc.

Cited by

See all 20

Metadata

Authors
Santos, M., Lima, L., Carvalho, S., Mota-Pereira, J., Pimentel, P., Maia, D., Correia, D., Barroso, M. F., Gomes, S., Cruz, A., & Medeiros, R.
Affiliations
  • IPO Porto (PT)
  • Experimental Pathology and Therapeutics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology, 4200-072 Porto, Portugal
  • Hospital de Magalhães Lemos (PT)
  • Clínica Médico-Psiquiátrica da Ordem, 4000-270 Porto, Portugal
  • Unidade Local de Saúde de Trás-os-Montes e Alto Douro (PT)
  • Rede de Química e Tecnologia (PT)
  • Centro de Investigação em Saúde e Ambiente (PT)
Corresponding author
  • Santos, Marlene
  • Medeiros, Rui
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-04-04
Volume
24
Issue
7
Pages
6758
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4362620113
Cited by
20
References
70
Citations by year
2026: 4 · 2025: 5 · 2024: 8 · 2023: 3
FWCI
3.10
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
Funders
AstraZeneca Foundation
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
antidepressant response, treatment-resistant depression, major depressive disorder, genetic polymorphism, brain-derived neurotrophic factor, NTRK2, nerve growth factor receptor, CREB1, GSK3B, Akt, MAPK1, mTOR, PTEN, Arc, synapsin I, relapse, neuroplasticity, BDNF/TrkB signaling, mTOR signaling, ERK signaling, synaptic transmission, predictive biomarkers
MeSH terms
Glycogen Synthase Kinase 3 beta, Antidepressive Agents, Major Depressive Disorder, Humans, Nerve Tissue Proteins, Phenotype, Recurrence, Cyclic AMP Response Element-Binding Protein, Receptors, Nerve Growth Factor, Brain-Derived Neurotrophic Factor, Mitogen-Activated Protein Kinase 1, Polymorphism, Single Nucleotide, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes. https://app.cochat.ai/papers/10.3390/ijms24076758
The paper
Santos, M., Lima, L., Carvalho, S., Mota-Pereira, J., Pimentel, P., Maia, D., Correia, D., Barroso, M. F., Gomes, S., Cruz, A., & Medeiros, R. (2023). The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076758

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.